Key result
Clopidogrel monotherapy reduced the 2-year composite of death, MI, stroke, ACS readmission, and major bleeding compared with aspirin monotherapy post-PCI.
Why the study?
Clopidogrel demonstrated superiority over aspirin monotherapy in secondary prevention after PCI, but whether these benefits extend across high-risk subgroups remained to be evaluated.
RCT (n=5,403)
randomly assigned
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Compared with aspirin monotherapy, the benefit of clopidogrel in reducing the composite thrombotic and bleeding outcomes was consistent and maintained in patients with high and low clinical, ischemic, and bleeding risks.”
“In our study, clopidogrel beat aspirin as a lifelong maintenance monotherapy after standard-duration dual antiplatelet therapy. Based on these results, I hope that guidelines will address clopidogrel monotherapy as comparable to aspirin monotherapy or as preferred to aspirin monotherapy for patients at high risk of recurrent ischemic events.”
“Now it's time for the comparison of monotherapies. Both SMART-CHOICE 3 and HOST-EXAM have compared clopidogrel and aspirin, but only in the 'remote' period after PCI when the overall thrombotic risk is lower for patients. What would be nice is to have a trial of P2Y12 inhibitor monotherapy versus aspirin after 3 to 6 months of DAPT in patients with acute coronary syndromes to see whether there is, of course, a benefit of P2Y12 inhibitor monotherapy versus aspirin as well.”
Risk-stratified antiplatelet therapy after PCI may warrant consideration; leaves open confirmation before practice change.
BACKGROUND Clopidogrel was superior to aspirin monotherapy in secondary prevention after percutaneous coronary intervention (PCI). OBJECTIVES The purpose of this study was to evaluate the benefits of clopidogrel across high-risk subgroups METHODS: This was a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy) trial that randomly assigned patients who were event free for 6 to 18 months post-PCI on dual antiplatelet therapy (DAPT) to clopidogrel or aspirin monotherapy. Two clinical risk scores were used for risk stratification: the DAPT score and the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS 2°P) (the sum of age ≥75 years, diabetes, hypertension, current smoking, peripheral artery disease, stroke, coronary artery bypass grafting, heart failure, and renal dysfunction). The primary composite endpoint was a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission because of acute coronary syndrome, and major bleeding (Bleeding Academic Research Consortium type ≥3) at 2 years after randomization. RESULTS Among 5,403 patients, clopidogrel monotherapy showed a lower rate of the primary composite endpoint than aspirin monotherapy (HR: 0.73; 95% CI: 0.59-0.90). The benefit of clopidogrel over aspirin was consistent regardless of TRS 2°P (high TRS 2°P [≥3] group: HR: 0.65 [95% CI: 0.44-0.96]; and low TRS 2°P [<3] group: HR: 0.77 [95% CI: 0.60-0.99]) (P for interaction = 0.454) and regardless of DAPT score (high DAPT score [≥2] group: HR: 0.68 [95% CI: 0.46-1.00]; and low DAPT score [<2] group: HR: 0.75 [95% CI: 0.59-0.96]) (P for interaction = 0.662). The association was similar for the individual outcomes. CONCLUSIONS The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy [HOST-EXAM]; NCT02044250).
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted an RCT in Post-percutaneous coronary intervention (n=5,403). Clopidogrel monotherapy vs. Aspirin monotherapy was evaluated on Composite of all-cause death, nonfatal myocardial infarction, stroke, readmission because of acute coronary syndrome, and major bleeding (Bleeding Academic Research Consortium type ≥3) (HR 0.73, 95% CI 0.59-0.90). Clopidogrel monotherapy reduced the 2-year composite of death, MI, stroke, ACS readmission, and major bleeding compared with aspirin monotherapy post-PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: